Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial.
무작위 임상시험
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
74 patients were randomly assigned to EUS-GE (38 patients) or SGJ (36 patients).
I · Intervention 중재 / 시술
EUS-GE and 38
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] In this randomised trial, EUS-GE was superior to SGJ with regards to oral intake, need for reinterventions or supplemental nutrition, length of hospitalisation, quality of life and treatment costs. [TRIAL REGISTRATION NUMBER] NCT05548114.
[BACKGROUND] Although surgical gastrojejunostomy (SGJ) is the standard method for palliation of gastric outlet obstruction (GOO), an endoscopic method-endoscopic ultrasound-guided gastroenterostomy (E
- p-value p=0.002
- p-value p=0.0016
APA
Bang JY, Puri R, et al. (2025). Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial.. Gut, 75(1), 24-32. https://doi.org/10.1136/gutjnl-2025-336339
MLA
Bang JY, et al.. "Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial.." Gut, vol. 75, no. 1, 2025, pp. 24-32.
PMID
40998416 ↗
Abstract 한글 요약
[BACKGROUND] Although surgical gastrojejunostomy (SGJ) is the standard method for palliation of gastric outlet obstruction (GOO), an endoscopic method-endoscopic ultrasound-guided gastroenterostomy (EUS-GE)-has been proposed as a novel, less invasive approach.
[OBJECTIVE] We compared both methods to determine whether clinical outcomes for EUS-GE are superior to surgery.
[DESIGN] We conducted a multicentre, randomised superiority trial of patients with malignant GOO to receive either EUS-GE or SGJ. Primary endpoint was composite measure, consisting of Gastric Outlet Obstruction Scoring System (GOOSS) score of 0 or 1 at hospital discharge, need for reinterventions or supplemental nutrition, or procedure-related adverse events during 6-month follow-up or until death. Secondary endpoints were time to solid diet, length of hospitalisation, health-related quality of life (HRQoL) and treatment costs.
[RESULTS] 74 patients were randomly assigned to EUS-GE (38 patients) or SGJ (36 patients). Primary endpoint occurred in 7.9% of patients who received EUS-GE and 38.9% in SGJ (risk difference -31.0%, 95% CI -47.6% to -11.4%, p=0.002). EUS-GE was associated with more rapid advancement to solid diet (median 2 days (P25-P75, 2-3) vs 5 days (P25-P75, 3.5-9)), shorter hospitalisation (median 3 days (P25-P75, 3-6) vs 9 days (P25-P75, 6-12.5)), better HRQoL for physical (p=0.0016) and social functioning (p=0.011) and lower treatment costs (US$33 934 vs US$51 437, difference -US$17 503 (95% CI -US$27 807 to -US$7920)).
[CONCLUSION] In this randomised trial, EUS-GE was superior to SGJ with regards to oral intake, need for reinterventions or supplemental nutrition, length of hospitalisation, quality of life and treatment costs.
[TRIAL REGISTRATION NUMBER] NCT05548114.
[OBJECTIVE] We compared both methods to determine whether clinical outcomes for EUS-GE are superior to surgery.
[DESIGN] We conducted a multicentre, randomised superiority trial of patients with malignant GOO to receive either EUS-GE or SGJ. Primary endpoint was composite measure, consisting of Gastric Outlet Obstruction Scoring System (GOOSS) score of 0 or 1 at hospital discharge, need for reinterventions or supplemental nutrition, or procedure-related adverse events during 6-month follow-up or until death. Secondary endpoints were time to solid diet, length of hospitalisation, health-related quality of life (HRQoL) and treatment costs.
[RESULTS] 74 patients were randomly assigned to EUS-GE (38 patients) or SGJ (36 patients). Primary endpoint occurred in 7.9% of patients who received EUS-GE and 38.9% in SGJ (risk difference -31.0%, 95% CI -47.6% to -11.4%, p=0.002). EUS-GE was associated with more rapid advancement to solid diet (median 2 days (P25-P75, 2-3) vs 5 days (P25-P75, 3.5-9)), shorter hospitalisation (median 3 days (P25-P75, 3-6) vs 9 days (P25-P75, 6-12.5)), better HRQoL for physical (p=0.0016) and social functioning (p=0.011) and lower treatment costs (US$33 934 vs US$51 437, difference -US$17 503 (95% CI -US$27 807 to -US$7920)).
[CONCLUSION] In this randomised trial, EUS-GE was superior to SGJ with regards to oral intake, need for reinterventions or supplemental nutrition, length of hospitalisation, quality of life and treatment costs.
[TRIAL REGISTRATION NUMBER] NCT05548114.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Aged
- Female
- Humans
- Male
- Middle Aged
- Endosonography
- Gastric Outlet Obstruction
- Gastroenterostomy
- Length of Stay
- Palliative Care
- Quality of Life
- Stomach Neoplasms
- Treatment Outcome
- Ultrasonography
- Interventional
- ENDOSCOPIC ULTRASONOGRAPHY
- GASTROINTESTINAL SURGERY
- INTESTINAL OBSTRUCTION
- PANCREATIC CANCER
- RANDOMIZED CONTROLLED TRIAL
같은 제1저자의 인용 많은 논문 (2)
- Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.
- Prospective clinical validation of a novel artificial intelligence system for real-time detection of solid pancreatic masses during endoscopic ultrasonography.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.